Infilea

Clobetasol Propionate, the active ingredient in Infilea, is a topical corticosteroid presented as a topical formulation for skin application. It is used to treat inflammatory dermatoses such as psoriasis, eczema and other severe skin conditions in adults and children when prescribed by a healthcare professional.

GNH USA supplies Infilea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clobetasol Propionate acts on inflammatory skin disorders by reducing cytokine‑mediated inflammation and immune cell activity. - Psoriasis: diminishes scaling, erythema and plaque thickness. - Atopic dermatitis (eczema): relieves itching, redness and edema. - Lichen planus: reduces violaceous papules and ulceration. - Discoid lupus erythematosus: controls chronic cutaneous lesions and prevents new lesion formation.

Clobetasol Propionate may cause local and systemic adverse reactions, most of which are dose‑ and duration‑dependent.

Common Side Effects: - Burning or stinging at the application site. - Pruritus or mild itching. - Dryness or flaking of the skin. - Folliculitis or acneiform eruptions. - Mild skin erythema.

Serious or Rare Side Effects: - Skin atrophy or thinning. - Telangiectasia (visible small blood vessels). - Hypopigmentation or depigmentation. - Secondary infection of treated area. - Systemic adrenal suppression with extensive use.

Clobetasol Propionate should be used with caution to minimize risks. - Limit application area: apply only to affected skin and avoid large surface areas. - Duration of therapy: restrict continuous use to the shortest period necessary, typically no longer than 2‑4 weeks. - Concomitant infections: avoid use on skin with bacterial, fungal or viral infections unless treated. - Pediatric use: exercise heightened caution in children due to increased systemic absorption. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Clobetasol Propionate can interact with other agents that affect corticosteroid metabolism or skin integrity.

Major Interactions (Avoid): - Concurrent systemic corticosteroids: may increase risk of systemic adrenal suppression. - Potent CYP3A4 inhibitors applied topically: may raise local drug concentration.

Moderate Interactions (Monitor Closely): - Antiviral or antifungal topical agents: may alter skin barrier and affect absorption. - Photosensitizing drugs (e.g., tetracyclines): increase risk of photosensitivity reactions. - Occlusive dressings: enhance percutaneous absorption, potentially leading to systemic effects.